Can an immune booster make hormone therapy work better against prostate cancer?

NCT ID NCT01688492

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial is testing whether adding an immunotherapy drug called ipilimumab to the standard hormone therapy of abiraterone plus prednisone can help men with advanced prostate cancer that has spread and no longer responds to hormone treatment. The study includes men aged 18 and older who have not yet had chemotherapy or immunotherapy. Participants receive the hormone therapy daily, and ipilimumab is given by infusion every three weeks for four doses. The goal is to see if the combination is safe and whether it can slow cancer progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ipilimumab combined with abiraterone acetate and prednisone
What this could lead to: If the combination works, it could offer a new way to slow or shrink advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is an early-phase trial with a small number of patients, so the benefits are uncertain. Combining these drugs may also increase side effects, including immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Northwestern University

Evanston, Illinois, 60208, United States
Oregon Health & Science University

Portland, Oregon, 97239, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.